The risk of serious bleeding in the presence of residual cangrelor effect is unknown. Based on the elimination half-life, we suggest that needle placement be avoided for 3 hours after discontinuation of cangrelor.

We suggest that neuraxial and deep plexus/peripheral catheters be removed prior to reinstitution of cangrelor therapy postoperatively.

We suggest that the first postoperative dose of cangrelor be administered 8 hours after neuraxial or deep plexus/peripheral catheter removal.

In patients receiving parenteral thrombin inhibitors, we suggest against the performance of neuraxial techniques.

Low-dose fondaparinux (2.5 mg once per day): We suggest holding low-dose fondaparinux (2.5 mg once per day) for 36 hours (young patients) to 42 hours (elderly patients) in healthy patients with normal renal function.

Low-dose fondaparinux: We suggest holding fondaparinux for a minimum of 58 hours in patients with moderate renal insufficiency (CrCl 30–50 mL/min).

Low-dose fondaparinux: We suggest not performing neuraxial or deep plexus/peripheral blocks in patients with severe renal impairment (CrCl<30 mL/min) due to the 72 hours half-life.

Low-dose fondaparinux: We suggest testing aXa activity calibrated to fondaparinux if placing the needle prior to these recommended times is considered (aXa ≤0.1 IU/mL).

High-dose fondaparinux (5–10 mg once per day): We suggest holding fondaparinux for a minimum of 70 hours in young patients with normal renal function.

High-dose fondaparinux: We suggest holding fondaparinux for a minimum of 105 hours in elderly patients with normal renal function.